These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38558765)

  • 1. Interassay Variability and Clinical Implications of Five Different Prostate-specific Antigen Assays.
    Kaufmann B; Pellegrino P; Zuluaga L; Ben-David R; Müntener M; Keller EX; Spanaus K; von Eckardstein A; Gorin MA; Poyet C
    Eur Urol Open Sci; 2024 May; 63():4-12. PubMed ID: 38558765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update.
    Stephan C; Klaas M; Müller C; Schnorr D; Loening SA; Jung K
    Clin Chem; 2006 Jan; 52(1):59-64. PubMed ID: 16391327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consistency and diagnostic accuracy of 4 assays in the detection of the total and free prostate-specific antigen.
    Deng L; Yue D; Wang X; Li H
    Transl Androl Urol; 2023 Feb; 12(2):261-270. PubMed ID: 36915871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing the impact of inter-method bias of prostate specific antigen assays on biopsy referral: the key to move towards precision health in prostate cancer management.
    Ferraro S; Biganzoli G; Bussetti M; Castaldi S; Biganzoli EM; Plebani M
    Clin Chem Lab Med; 2023 Jan; 61(1):142-153. PubMed ID: 36322977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
    Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordant prostate specific antigen test results despite WHO assay standardization.
    Boegemann M; Arsov C; Hadaschik B; Herkommer K; Imkamp F; Nofer JR; Gerß J; Albers P; Semjonow A
    Int J Biol Markers; 2018 Aug; 33(3):275-282. PubMed ID: 29734838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards.
    Stephan C; Kahrs AM; Klotzek S; Reiche J; Müller C; Lein M; Deger S; Miller K; Jung K
    Clin Chem Lab Med; 2008; 46(5):623-9. PubMed ID: 18839463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening SA
    Anticancer Res; 2000; 20(6D):4997-5001. PubMed ID: 11326657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Three Assays for Total and Free PSA Using Hybritech and WHO Calibrations.
    Garrido MM; Marta JC; Ribeiro RM; Pinheiro LC; Holdenrieder S; Guimarães JT
    In Vivo; 2021; 35(6):3431-3439. PubMed ID: 34697179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
    Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
    Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
    Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation.
    Kort SA; Martens F; Vanpoucke H; van Duijnhoven HL; Blankenstein MA
    Clin Chem; 2006 Aug; 52(8):1568-74. PubMed ID: 16762996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standardization of assay methods reduces variability of total PSA measurements: an Irish study.
    Forde JC; Marignol L; Blake O; McDermott T; Grainger R; Crowley VE; Lynch TH
    BJU Int; 2012 Sep; 110(5):644-50. PubMed ID: 22897326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
    Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
    Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy.
    Wesseling S; Stephan C; Semjonow A; Lein M; Brux B; Sinha P; Loening SA; Jung K
    Clin Chem; 2003 Jun; 49(6 Pt 1):887-94. PubMed ID: 12765984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?
    Jung K; Stephan C; Elgeti U; Lein M; Brux B; Kristiansen G; Rudolph B; Hauptmann S; Schnorr D; Loening SA; Sinha P
    Int J Cancer; 2001 Sep; 93(5):759-65. PubMed ID: 11477592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of free-to-total prostate specific antigen variability on the early diagnosis of prostate cancer: a comparative study of three immunoassays.
    de la Taille A; Houlgatte A; Houdelette P; Goluboff ET; Berlizot P; Ricordel I
    Br J Urol; 1998 Sep; 82(3):389-92. PubMed ID: 9772876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL.
    Okegawa T; Kinjo M; Ohta M; Miura I; Horie S; Nutahara K; Higashihara E
    Int J Urol; 2003 Apr; 10(4):201-6. PubMed ID: 12657099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics.
    Stephan C; Cammann H; Meyer HA; Müller C; Deger S; Lein M; Jung K
    BJU Int; 2008 Sep; 102(7):799-805. PubMed ID: 18522632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.